Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL)

Trial Profile

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Ganetespib (Primary) ; Ganitumab (Primary) ; MK 2206 (Primary) ; Neratinib (Primary) ; Patritumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; SGN LIV1A (Primary) ; Trastuzumab (Primary) ; Trebananib (Primary) ; Veliparib (Primary) ; Carboplatin; Conatumumab; Cyclophosphamide; Doxorubicin; Figitumumab; Metformin; Paclitaxel; Talazoparib; Trastuzumab emtansine
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms I-SPY-2
  • Most Recent Events

    • 11 Oct 2017 According to a Seattle Genetics media release, SGN-LIV1A in combination with standard chemotherapy will also be evaluated as neoadjuvant treatment in the phase 2 I-SPY 2 TRIAL for newly diagnosed Stage 2 or 3 human epidermal growth factor receptor 2 (HER2) negative breast cancer.
    • 13 Jun 2017 Results published in an Agendia media release.
    • 05 Jun 2017 Results from the parant study published in a Merck AG Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top